Covered recipient · General Payments record
CHARLES A POWELL
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
General Payments · PY2018–2024
$611,683.78
- Reported across 120 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $109,746.00 | 15 |
| Food and Beverage | $159.00 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $99,187.50 | 11 |
| BioNTech SE | $9,621.00 | 3 |
| PFIZER INC. | $937.50 | 1 |
| Acerta Pharma LLC | $159.00 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $101.13 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105752747 | CMS |
| AstraZeneca Pharmaceuticals LP | $57.87 | 05/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104677719 | CMS |
| BioNTech SE | $821.00 | 02/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1150660566 | CMS |
| BioNTech SE | $4,400.00 | 03/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1150660562 | CMS |
| BioNTech SE | $4,400.00 | 04/30/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1150660564 | CMS |
| Daiichi Sankyo Inc. | $6,750.00 | 01/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470651 | CMS |
| Daiichi Sankyo Inc. | $7,312.50 | 02/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470645 | CMS |
| Daiichi Sankyo Inc. | $12,562.50 | 03/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470643 | CMS |
| Daiichi Sankyo Inc. | $8,625.00 | 04/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470641 | CMS |
| Daiichi Sankyo Inc. | $8,437.50 | 05/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470647 | CMS |
| Daiichi Sankyo Inc. | $7,875.00 | 06/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470637 | CMS |
| Daiichi Sankyo Inc. | $5,250.00 | 07/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470655 | CMS |
| Daiichi Sankyo Inc. | $12,187.50 | 08/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470639 | CMS |
| Daiichi Sankyo Inc. | $9,187.50 | 09/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470653 | CMS |
| Daiichi Sankyo Inc. | $14,062.50 | 11/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470649 | CMS |
| Daiichi Sankyo Inc. | $6,937.50 | 12/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089470635 | CMS |
| PFIZER INC. | $937.50 | 01/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1132053658 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.